Comparison of Three Different Glucose-lowering Drugs on Serum Levels of Glucose and Pancreas Histopathology in Streptozotocin-Induced Diabetic Rats

Main Article Content

Alireza Sadeghi
Ali Shabestari Asl
Daryoush Babazadeh
Pouria Ahmadi Simab


Introduction: Diabetes mellitus is a metabolic disorder resulting from a defect in insulin secretion, insulin action, or both. The aim of the present study was to compare the effect of three different blood glucose-lowering drugs in streptozotocin-induced diabetic rats.  

Materials and methods: A total of 60 male Wistar rats (220–250 g and 2-3 months of age) were selected for the current study, and they then were divided into five equal groups. Group 1 included healthy control rats receiving standard diet, group 2 involved diabetic rats receiving standard diet plus acarbose (25mg/kg/day) via gastric feeding tube daily for 8 weeks, group 3 embraced diabetic rats receiving standard diet plus pioglitazone (1 mg/kg/day) via gastric feeding tube daily for 4 weeks, and group 4 received of diabetic rats receiving standard diet plus repaglinide (10 mg/kg/day) via gastric feeding tube daily for 4 weeks. Diabetes was induced by intraperitoneal injection of streptozotocin at a dosage of 65 mg/kg body weight. At the end of the study, the samples were taken for histopathological investigation of pancreas and serum glucose levels. The mean diameter of pancreatic islets and the percentage of beta and alpha cells were calculated in all groups.

Results: The fasting blood glucose in three treated and normal control rats was significantly less than the diabetic control group. One hour after treatment the blood glucose level reduced significantly in three treated and normal control rats compared to the diabetic control group. On day 7, the percentage of alpha cells in the pioglitazone and acarbose groups increased significantly, compared to the diabetic control group. On day 28, the percentage of beta cells in the treated groups increased significantly, compared to normal and diabetic control groups. Moreover, the mean of islet diameter in the treated groups increased significantly, compared to the normal and diabetic control groups. The percentage of alpha cells in the repaglinide group significantly reduced on day 28, compared to the diabetic control group.

Conclusion: Among the administrated drugs, pioglitazone had the most positive effects on controlling blood glucose, increasing beta cells as well as improving the diameter of pancreatic islets.

Article Details

How to Cite
Sadeghi, A., Shabestari Asl, A., Babazadeh, D., & Ahmadi Simab, P. (2022). Comparison of Three Different Glucose-lowering Drugs on Serum Levels of Glucose and Pancreas Histopathology in Streptozotocin-Induced Diabetic Rats. Journal of Veterinary Physiology and Pathology, 1(1), 37–42.
Original Articles


Adeghate E, Howarth F C, Jacobson M, and Shafiullah M. Effects of insulin treatment on heart rhythm, body temperature and physical activity in streptozotocin‐induced diabetic rat. Clin Exp Pharmacol Physiol.

; 33: 327-331. DOI:

Alberti KG, and Zimmet PZ. New diagnostic criteria and classification of diabetesagain. Diabet Med. 1998; 15: 535-536. DOI:<535::AID-DIA670>3.0.CO;2-Q

Wright B E, Vasselli J R, and Katovich MJ. Positive effects of acarbose in the diabetic rat are not altered by feeding schedule. Physiol Behav.1998; 63: 867-874. DOI:

Kawamura T, Egusa G, Fujikawa R, Watanabe T, Oda K, Kataoka S, and Yamakido M. Effect of acarbose on glycemic control and

lipid metabolism in patients with non-insulin dependent

diabetes mellitus. Curr Ther Res. 1998; 59: 97-106. DOI:

Hua Y, Keep RF, Hoff JT, and Xi G. Thrombin preconditioning attenuates brain edema induced by erythrocytes and iron. J

Cereb Blood Flow Metab. 2003; 23(12): 1448-1454. DOI:

Standl E, Baumgartl HJ, Füchtenbusch M, and Stemplinger JE. Effect of acarbose on additional insulin therapy in type 2 diabetic patients with late failure of sulphonylurea therapy. Diabetes Obes Metab.1999; 1: 215-220.‏ DOI:

Hanefeld M. The role of acarbose in the treatment of noninsulin-dependent diabetes mellitus. J Diabetes Complications. 1998; 12: 228-237. DOI:

Fischer S, Hanefeld M, Spengler M, Boehme K, and Temelkova-Kurktschiev T. European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: efficacy and safety of low and high doses. Acta Diabetol. 1998; 35(1): 34-40. DOI:

Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, Ryan EA, and Tan MH, Wolever TM. The efficacy of acarbose in the treatment of patients with non–insulin-dependent diabetes mellitus: A multicenter, controlled clinical trial. Ann Intern Med. 1994; 121(12): 928-935. DOI:

Cheng AY, and Fantus IG. Oral antihyperglycemic therapy for type

diabetes mellitus. CMAJ. 2005; 172(2): 213-226. DOI:

Tjokroprawiro A. Thyroid storm: A life-threatening thyrotoxicosis Therapeutic Clinical Experiences with Formula TS 41668-24-6.

Folia Med Indonesia. 2006; 42: 271-276. Available at:

Colca JR, McDonald WG, Waldon DJ, Leone JW, Lull JM, Bannow CA et al. Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe. Am. J.

Physiol. Endocrinol. Metab. 2004; 286(2): 252-260. DOI:

‏Paddock ML, Wiley SE, Axelrod HL, Cohen AE, Roy M, Abresch EC et al. MitoNEET is a uniquely folded 2Fe 2S outer mitochondrial membrane protein stabilized by pioglitazone. Proc Natl Acad Sci USA. 2007; 104(36): 14342-14947. DOI:

Waugh J, Keating GM, Plosker GL, Easthope S, and Robinson DM. Pioglitazone. Drugs. 2006; 66(1): 85-109. Available at:

Dhole SM, Khedekar PB, and Amnerkar ND. Comparison of UV spectrophotometry and high performance liquid chromatography methods for the determination of repaglinide in tablets. Pharm Methods, 2012; 3(2): 68-62. DOI:

Lauri IK, and Jouko L. Metabolism of Repaglinide by CYP2C8 and CYP3A4 in vitro: Effect of Fibrates and Rifampicin, Basic Clin Pharmacol Toxicol. 2005; 97: 249-456. DOI:

Gupta RK, Kesari AN, Murthy PS, Chandra R, Tandon V, and Watal G. Hypoglycemic and antidiabetic effect of ethanolic extract of leaves of Aannona squamosa L. in experimental animals. J Ethnopharmacol. 2005; 99: 75-81. DOI:

Thiemermann C, Patel NS, Kvale EO, Cockerill GW, Brown PAJ, Stewart KN et al. High density lipoprotein (HDL) reduces renal ischemia/reperfusion injury. J Am Soc Nephrol. 2003; 14: 1833-1843. DOI:

Singh D, Chander V, and Chopra K. Protective effect of catechin on ischemia-reperfusion-induced renal injury in rats. Pharmacol Rep. 2005; 7: 70-76. Available at:


Chen H, Xing B, Liu X, Zhan B, Zhou J, Zhu H et al. Ozone oxidative preconditioning inhibits inflammation and apoptosis in a rat model of renal ischemia/reperfusion injury. Eur J Pharmacol. 2008; 581: 306-314.DOI:

Bhalodia Y, Kanzariya N, Patel R, Patel N, Vaghasiya J, Jivani N et al. Renoprotective activity of benincasa cerifera fruit extract on ischemia/reperfusion-induced renal damage in rat. IJKD. 2009; 3(2): 80-85. Available at:


American Diabetes Association. Nutrition recommendations and interventions for diabetes: A position statement of the American Diabetes Association. Diabetes Care. 2007; 3: 48-65. DOI:

Hove MN, Kristensen JK, Lauritzen T, and Bek T. The prevalence of retinopathy in an unselected population of type 2 diabetes patients from Arhus County, Denmark. Acta Ophthalmol Scand, 2004; 82: 443-448. DOI:

Moran A, Palmas W, Field L, Bhattarai J, Schwartz JE, Weinstock RS

et al. Cardiovascular autonomic neuropathy is associated with microalbuminuria in older patients with type 2 diabetes. Diabetes care. 2004; 27: 972-977. DOI:

Shukla N, Angelini GD, Jeremy JY. —to: Looker HC, Fagot-Campagna A, Gunter EW et al. (2003). Homocysteine as a risk factor for nephropathy and retinopathy in type 2 diabetes. Diabetologia 46: 766–772. Diabetologia. 2004; 47(1): 140-141. Available at:

Svensson M, Eriksson JW, and Dahlquist G. Early glycemic control, age at onset, and development of microvascular complications in childhood-onset type 1 diabetes: A population-based study in northern Sweden. Diabetes Care. 2004; 27: 955-962. DOI:

Wallace C, Reiber GE, LeMaster J, Smith DG, Sullivan K, Hayes S et al. Incidence of falls, risk factors for falls, and fall-related factures in individuals with diabetes and a prior foot ulcer. Diabetes Care. 2002; 25: 1983-1986. DOI:

Zimmet P, Cowie C, Ekoe JM, and Shaw JE. Classification of diabetes mellitus and other categories of glucose intolerance. In: De Fronzo RA, Ferrannini E, Keen H, and Zimmet P editors.International Textbook of Diabetes Mellitus. 3rd ed, John Wiley and Sons, Ltd. 2004;1: 3-14. DOI:

DeFronzo RA, Bonadonna RC, and Ferrannini. Pathogenesis of NIDDM. In: Albert KGMM, Zimmet P, and DeFronzo RA editors. International Textbook of Diabetes Mellitus, 2nd ed. Chichester, Wiley.

; p. 635-612.. DOI:<979::AID-DIA695>3.0.CO;2-9

Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: The third National Health and Nutritional Examination Survey, 1988-1994. Diabetes Care. 1998; 21: 518-524. DOI:

King H, Aubert R, and Herman W. Global burden of diabetes: Prevalence, numerical estimates and projections. Diabetes Care. 1998; 21: 1414-1431. DOI:

Wu QL, Liu YP, Lu JM, Wang CJ, Yang T, Dong JX et al. Efficacy and safety of acarbose chewable tablet in patients with type 2 diabetes: A multicentre, randomized, double-blinded, double-dummy positive controlled trial. J Evid Based Med. 2012; 5(3): 134-138. DOI:

Mughal MA, Memon MY, and Zardari MK. Effect of acarbose on glycemic control, serum lipids and lipoproteins in type 2

diabete. UPMA. 2000; 50: 152-160. Available at:

Zhu Q, Tong Y, Wu T, Li J, and Tong N. Comparison of the hypoglycemic effect of acarbose monotherapy in patients with type 2 diabetes mellitus consuming an eastern or western diet: A systematic meta-analysis. Clin Ther. 2013; 35(6): 880-899. DOI:

Defronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA et al. Prevention of diabetes with pioglitazone in Act Now: Physiologic correlates. Diabetes. 2013; 62: 3920-3926. DOI:

Gad MZ, Ehssan NA, Ghiiet MH, and Wahman LF. Pioglitazone versus metformin in two rat models of glucose intolerance and diabetes.

Pak J Pharm Sci. 2010; 23: 305-312. Available at:

Tripathy D, Daniele G, Fiorentino TV, Perez-Cadena Z, Chavez-Velasquez A, Kamath S et al. Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: A randomised, double-blind, placebo-controlled, mechanistic study. Diabetologia. 2013; 56(10): 2153-2163. DOI:

Matsumoto T, Noguchi E, Kobayashi T, and Kamata K. Mechanisms underlying the chronic pioglitazone treatment-induced improvement in the impaired endothelium-dependent relaxation seen in aortas from diabetic rats. Free Radical Biology and Medicine. 2007; 42(7): 993-1007. DOI:

Hezarkhani S, Bonakdaran S, Rajabian R, Shahini N, and Marjani A. Comparison of glycemic excursion in patients with new onset type 2 diabetes mellitus before and after treatment with repaglinide. Open Biochem J. 2013; 7: 19-23. DOI:


Manzella D, Grella R, Abbatecola AM, and Paolisso G. Repaglinide administration improves brachial reactivity in type 2 diabetic patients. Diabetes Care. 2005; 28(2): 366-371. DOI:

Stein SA, Lamos EM, and Davis SN. A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin Drug Saf. 2013; 12(2): 153-175. DOI: